

SANDOZ



**Information
about biosimilars**

Since January 2024, pharmacists have the permission to offer you biosimilars. You can find helpful information here:

What is a biosimilar?

A biosimilar is the follow-on drug to a formerly patent-protected biologic (= reference medicine).

Same
active
ingredient



More information, including short videos in many languages, can be found at www.biosimilar-infothek.ch



A biosimilar matches its reference medicine and is therefore interchangeable with it:

- Same active ingredient, same mode of action
- Quality, efficacy and safety confirmed by the Swiss regulatory authority (Swissmedic)
- Interchangeability confirmed by Swissmedic

How long have biosimilars been around?

Biosimilars have been used in Switzerland since 2009. The proportion of biosimilars is rising steadily.

15 years
experience

Why choose a biosimilar?


Biosimilars are more cost-effective, equivalent alternatives to the corresponding reference medicine.

- Consistent use of biosimilars in Switzerland could reduce the burden on the healthcare system. Around CHF 100 million could have been saved in 2023.
- Biosimilars contribute to the long-term financial viability of the Swiss healthcare system.

Cost
benefit

This is SANDOZ

SANDOZ is a **Swiss company** based in Basel and a pioneer in the field of biosimilars in Europe.



The **services provided by SANDOZ** go beyond the provision of standard products and thus create added value for the Swiss healthcare system. Your pharmacy and your doctor can provide you with further information.



Sandoz Pharmaceuticals AG,
Suurstoffi 14, 6343 Rotkreuz,
Tel. 0800 858 885, www.mysandoz.ch

SANDOZ